Acciones Isodiol International Inc. Canadian Securities Exchange
Acciones
ISOL
CA46500L2003
Farmacéuticos
Ventas 2018 | 19,14 M 26,32 M 17,89 M | Ventas 2019 | 22,25 M 30,6 M 20,8 M | Capitalización | 49,96 M 68,71 M 46,7 M |
---|---|---|---|---|---|
Resultado Neto 2018 | -36 M -49,52 M -33,66 M | Resultado Neto 2019 | -126 M -173 M -118 M | VE / Ventas 2018 | 12,6 x |
Posición de caja neta 2018 | 15,55 M 21,39 M 14,54 M | Deuda neta 2019 | 5,22 M 7,18 M 4,88 M | VE / Ventas 2019 | 2,48 x |
P/E ratio 2018 |
-4,94
x | P/E ratio 2019 |
-0,37
x | Empleados | - |
Rendimiento 2018 * |
-
| Rendimiento 2019 |
-
| Flotante | 100 % |
Directores | Puesto | Edad | Desde |
---|---|---|---|
Marcos Agramont
CEO | Chief Executive Officer | - | 24/05/17 |
Director/Board Member | - | 30/08/18 | |
Kevin Swadish
PRN | Corporate Officer/Principal | - | 14/02/19 |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Marcos Agramont
CEO | Chief Executive Officer | - | 24/05/17 |
Director/Board Member | - | 30/08/18 | |
Director/Board Member | - | 21/11/18 |
Varia. 1 de ene. | Capi. | |
---|---|---|
+32,81 % | 5816,71 M | |
-25,27 % | 3971,95 M | |
+5,41 % | 3306,83 M | |
-21,39 % | 2756,5 M | |
-11,93 % | 2263,02 M | |
+44,07 % | 1916,95 M | |
-17,86 % | 1496,5 M | |
+43,25 % | 1476,94 M | |
-9,38 % | 1490,01 M |